PMID- 34810088
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20220221
IS  - 1444-2892 (Electronic)
IS  - 1443-9506 (Linking)
VI  - 31
IP  - 3
DP  - 2022 Mar
TI  - Iron Deficiency in Heart Failure Patients and Benefits of Iron Replacement on 
      Clinical Outcomes Including Comorbid Depression.
PG  - 313-326
LID - S1443-9506(21)01309-3 [pii]
LID - 10.1016/j.hlc.2021.10.013 [doi]
AB  - BACKGROUND: Iron deficiency and depression are prevalent comorbidities in the 
      setting of heart failure. Both conditions are associated with poorer patient 
      outcomes including mortality, hospitalisation and quality of life. Iron 
      replacement has come to the fore as a means to improve patient outcomes. This 
      review aims to assess the current literature regarding the benefits of iron 
      supplementation for iron deficient heart failure patients including potential 
      improvements in depression. METHODS AND RESULTS: The databases of Medline, 
      EMBASE, the Cochrane library of systematic reviews, Central Register of 
      Controlled Trials, PubMed, Web of Science and ClinicalTrials.gov were searched 
      for studies with relevant patient outcomes. A total of 18 studies were identified 
      and included in the review. In essence, intravenous iron was found to be 
      beneficial for New York Heart Association (NYHA) classification, quality of life 
      measures, heart failure (HF) hospitalisation and aerobic capacity. Oral iron 
      however was not beneficial. Research surrounding intravenous iron improving 
      cardiovascular mortality, time to first hospitalisation and changes in depression 
      status is lacking. CONCLUSIONS: Further research is required to elucidate the 
      advantages of intravenous iron for iron deficient heart failure patients on their 
      depression, mortality and first admission to hospital. Consensus is required 
      regarding which form of iron and the treatment regime that should be adopted for 
      future clinical guidelines.
CI  - Copyright (c) 2021. Published by Elsevier B.V.
FAU - Huang, Kevin W
AU  - Huang KW
AD  - University of Melbourne Medical School, Melbourne, Vic, Australia; Department of 
      Cardiology Austin Health, Melbourne, Vic, Australia.
FAU - Bilgrami, Nazar L
AU  - Bilgrami NL
AD  - Department of Cardiology Austin Health, Melbourne, Vic, Australia.
FAU - Hare, David L
AU  - Hare DL
AD  - Department of Cardiology Austin Health, Melbourne, Vic, Australia; Department of 
      Medicine, University of Melbourne, Melbourne, Vic, Australia. Electronic address: 
      david.hare@unimelb.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211120
PL  - Australia
TA  - Heart Lung Circ
JT  - Heart, lung & circulation
JID - 100963739
RN  - E1UOL152H7 (Iron)
SB  - IM
MH  - Depression/drug therapy/epidemiology
MH  - *Heart Failure/complications/drug therapy/epidemiology
MH  - Humans
MH  - Iron
MH  - *Iron Deficiencies
MH  - Quality of Life
MH  - Systematic Reviews as Topic
OTO - NOTNLM
OT  - Depression
OT  - Heart failure
OT  - Iron deficiency
OT  - Iron infusion
OT  - Iron replacement
OT  - Patient outcomes
EDAT- 2021/11/24 06:00
MHDA- 2022/02/22 06:00
CRDT- 2021/11/23 05:50
PHST- 2021/01/07 00:00 [received]
PHST- 2021/08/14 00:00 [revised]
PHST- 2021/10/16 00:00 [accepted]
PHST- 2021/11/24 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/11/23 05:50 [entrez]
AID - S1443-9506(21)01309-3 [pii]
AID - 10.1016/j.hlc.2021.10.013 [doi]
PST - ppublish
SO  - Heart Lung Circ. 2022 Mar;31(3):313-326. doi: 10.1016/j.hlc.2021.10.013. Epub 
      2021 Nov 20.